See more : ByggPartner Gruppen AB (publ) (BYGGP.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Strongbridge Biopharma plc (SBBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Strongbridge Biopharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Gongin Precision Ind. Co., Ltd (3178.TWO) Income Statement Analysis – Financial Results
- Omni Financial Services, Inc. (OFSI) Income Statement Analysis – Financial Results
- Timberline Resources Corporation (TLRS) Income Statement Analysis – Financial Results
- Chacha Food Company, Limited (002557.SZ) Income Statement Analysis – Financial Results
- Cloetta AB (publ) (CLA-B.ST) Income Statement Analysis – Financial Results
Strongbridge Biopharma plc (SBBP)
About Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.73M | 21.71M | 18.03M | 7.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.21M | 3.82M | 3.99M | 1.48M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 28.52M | 17.89M | 14.04M | 5.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 92.80% | 82.40% | 77.89% | 78.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.80M | 30.90M | 25.44M | 17.27M | 20.02M | 20.14M | 5.84M | 2.53M |
| General & Administrative | 40.87M | 45.81M | 63.34M | 36.29M | 14.88M | 22.72M | 4.59M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.87M | 45.81M | 63.34M | 36.29M | 14.88M | 22.72M | 4.59M | 0.00 |
| Other Expenses | 5.02M | 5.02M | 7.19M | 5.02M | 0.00 | 0.00 | 0.00 | -7.73M |
| Operating Expenses | 71.68M | 81.74M | 95.96M | 58.58M | 34.90M | 42.85M | 10.43M | -5.19M |
| Cost & Expenses | 73.90M | 85.56M | 99.95M | 60.07M | 34.90M | 42.85M | 10.43M | 5.19M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 25.00K | 0.00 | 0.00 |
| Interest Expense | 1.34M | 0.00 | 12.52M | 4.31M | 20.00K | 3.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.11M | 5.10M | 7.23M | 5.03M | 10.00K | 11.00K | 6.00K | 3.00K |
| EBITDA | -38.65M | -42.58M | 52.14M | -102.37M | -51.21M | -44.02M | -10.14M | -5.39M |
| EBITDA Ratio | -125.76% | -196.13% | 289.21% | -1,452.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.17M | -63.85M | -81.92M | -53.02M | -34.90M | -42.85M | -10.43M | -5.19M |
| Operating Income Ratio | -140.46% | -294.05% | -454.45% | -752.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.93M | 16.16M | 114.31M | -58.69M | -16.46M | -1.23M | 282.00K | -288.00K |
| Income Before Tax | -45.09M | -47.68M | 32.39M | -111.71M | -51.36M | -44.08M | -10.15M | -5.48M |
| Income Before Tax Ratio | -146.72% | -219.62% | 179.66% | -1,585.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -15.00K | 1.77M | 536.00K | 1.77M | -2.64M | -450.00K | -480.00K | -93.00K |
| Net Income | -45.08M | -49.45M | 31.85M | -113.48M | -48.60M | -43.58M | -9.67M | -5.30M |
| Net Income Ratio | -146.68% | -227.76% | 176.68% | -1,610.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.80 | -0.89 | 0.64 | -3.11 | -2.26 | -2.62 | -0.96 | -0.88 |
| EPS Diluted | -0.80 | -0.89 | 0.64 | -3.11 | -2.24 | -2.62 | -0.96 | -0.88 |
| Weighted Avg Shares Out | 56.11M | 55.38M | 49.72M | 36.54M | 21.55M | 16.61M | 10.11M | 6.02M |
| Weighted Avg Shares Out (Dil) | 56.11M | 55.38M | 49.72M | 36.54M | 21.66M | 16.61M | 10.11M | 6.02M |
Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it...
Strongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve
~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~
Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing's Syndrome
DUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Strongbridge Biopharma plc - SBBP
NEW YORK, May 29, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New...
STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Strongbridge Biopharma plc (NasdaqGS: SBBP) to Xeris Pharmaceuticals, Inc. (NasdaqGS: XERS)....
STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Strongbridge Biopharma plc (NasdaqGS: SBBP) to Xeris Pharmaceuticals, Inc. (NasdaqGS: XERS)....
Strongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SBBP
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Strongbridge Biopharma plc (NASDAQ: SBBP) to Xeris Pharmaceuticals, Inc. is fair to Strongbridge shareholders. Under the terms of the merger, Strongbridge shareholders will...
Strongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SBBP
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Strongbridge Biopharma plc (NASDAQ: SBBP) to Xeris Pharmaceuticals, Inc. is fair to Strongbridge shareholders. Under the terms of the merger, Strongbridge shareholders will...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Strongbridge Biopharma plc
NEW YORK, May 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NASDAQ: SBBP) in connection with the Company's proposed merger...
Source: https://incomestatements.info
Category: Stock Reports